Evolution of biomarker qualification at the health authorities

Nature Biotechnology

Volumn 28, Issue 5, 2010, Pages 441-443

  Goodsaid, Federico ^a   Papaluca, Marisa ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; GENOME; HEALTH CARE ORGANIZATION; NOTE; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL MARKERS; DRUG DISCOVERY; EUROPE; HUMANS; JAPAN; REFERENCE STANDARDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77952175271     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0510-441     Document Type: Note

References (19)

1. European Agency for the Evaluation of Medical Products. Public Statement: EU-US FDA Bilateral Agreement (EMEA, London, UK 2003; accessed 8 September 2009). http://www.emea.europa.eu/pdfs/general/direct/pr/2447803en.pdf
2. The Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions (FDA, Rockville, Maryland, USA, March 2005; accessed 8 September 2009). http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079849.pdf
3. European Agency for the Evaluation of Medical Products. Medicines and Emerging Science (EMEA, London, UK, accessed 8 September 2009) http://www.emea.europa.eu/htms/human/mes/emergingtechnologies.htm
4. The Food and Drug Administration. Fed. Reg. 69, 48876-48877 (2004). http://www.fda.gov/OHRMS/DOCKETS/98fr/04-18360.htm
5. The European Medicines Agency. EMEA/CHMP/PGxWP/20227/04 Guideline on Pharmacognetics Briefing Meetings (EMEA, London, UK 2004; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/pharmacogenetics/2022704en.pdf
6. Uyama, Y. Nippon Yakurigaku Zasshi 126, 432-435 (2005).
7. The Food and Drug Administration. Critical Path Initiative (FDA, Rockville, Maryland, USA, (2004)
8. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ default.htm
9. The European Medicines Agency. The European Medicines Agency Road Map to 2015: Preparing the Ground for the Future (EMEA, London, UK, 2010; 8 September 2009). http://www.emea.europa.eu/htms/general/direct/roadmap/roadmapintro.htm
10. The European Medicines Agency. Innovative Drug Development Approaches (EMEA/127318/2007)\Final Report of the EMEA/CHMP Think-Tank on Innovative Drug Development (EMEA, London, UK 2007; accessed 8 September 2009). http://www.ema. europa.eu/pdfs/human/itf/12731807en.pdf
11. Goodsaid, F.M., Frueh, F.W. & Mattes, W. Toxicology. 245, 219-223 (2008)
12. Hunter, A.J. Drug Discov. Today. 13, 371-373 (2008).
13. The European Medicines Agency. Final Report on the Pilot Joint EMEA/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers (EMEA, London, UK, May 2008; accessed 8 September 2009). http://www.ema. europa.eu/pdfs/human/ biomarkers/25088508en.pdf
14. Altar, C.A. et al. Clin. Pharmacol. Ther. 83, 368-371 (2008).
15. Lathia, C.D. et al. Clin. Pharmacol. Ther. 86, 32-43 (2009).
16. The Food and Drug Administration. E16 Genomic Biomarkers Related to Drug Response: Context, Structure, and Format of Qualification Submissions (FDA, Rockville, Maryland, USA; accessed 8 September 2009). http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174433.pdf
17. The Food and Drug Administration. Fed. Reg. 69, 42060-42061 (2004; accessed 8 September 2009). http://www.fda.gov/OHRMS/DOCKETS/98fr/04-15935.htm
18. The Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels (FDA, Rockville, Maryland, USA; accessed 8 September 2009). http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm083378.htm.
19. The European Medicines Agency. Guidance Document on the Qualification of Novel Methodologies for Drug Development (EMEA, London, UK, January 2009; accessed 8 September 2009). http://www.ema.europa. eu/pdfs/human/biomarkers/ 7289408en.pdf